ciraparantag
Small moleculeexperimental
Ciraparantag (aripazine) is a drug under investigation as an antidote for a number of anticoagulant drugs, including factor Xa inhibitors, dabigatran, and heparins. — Wikipedia
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01826266)
Timeline
Indications
Mechanism of action
- ApixabanSEQUESTERING AGENT
Apixaban sequestering agent
Antidote for anticoagulant drugs.
- HeparinSEQUESTERING AGENT
Heparin sequestering agent
Antidote for anticoagulant drugs.
- DabigatranSEQUESTERING AGENT
Dabigatran sequestering agent
Antidote for anticoagulant drugs.
- EdoxabanSEQUESTERING AGENT
Edoxaban sequestering agent
Antidote for anticoagulant drugs.
- RivaroxabanSEQUESTERING AGENT
Rivaroxaban sequestering agent
Antidote for anticoagulant drugs.
- HeparinINHIBITOR
Heparin inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N=C(N)NCCC[C@H](N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(=N)N)CC1- Mol. weight
- 512.71 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCiraparantag ↗
- ChEMBLCHEMBL3544919 ↗
Also known as
- ciraparantag
- ciraparantag
- ciraparantag
- ciraparantag
- per977
- per977
- per977
- per-977
- per-977
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04593784 | Phase 2 | Nov 1, 2020 | AMAG Pharmaceuticals, Inc. |
| NCT03288454 | Phase 2 | Sep 10, 2017 | Perosphere, Inc. |
| NCT03172910 | Phase 2 | May 8, 2017 | Perosphere, Inc. |
| NCT02205905 | Phase 1 | Jul 1, 2014 | Perosphere, Inc., Worldwide Clinical Trials, World Wide Clinical Trials Early Phase Services, LLC |
| NCT02206087 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | IQVIA, Perosphere, Inc. |
| NCT02206100 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | IQVIA, Perosphere, Inc. |
| NCT02207257 | Phase 2 | Mar 1, 2014 | IQVIA, Perosphere, Inc. |
| NCT01826266 | Phase 1 | Jul 1, 2013 | Duke University, Perosphere, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Perosphere, Inc. | For profit | 7 | 7 | 2 | 2013 |
| IQVIA | For profit | 3 | 0 | 1 | 2014 |
| AMAG Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2014 |
| World Wide Clinical Trials Early Phase Services, LLC | For profit | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1